GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lee's Pharmaceutical Holdings Ltd (STU:L1PA) » Definitions » Current Ratio

Lee's Pharmaceutical Holdings (STU:L1PA) Current Ratio : 1.10 (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lee's Pharmaceutical Holdings Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Lee's Pharmaceutical Holdings's current ratio for the quarter that ended in Jun. 2024 was 1.10.

Lee's Pharmaceutical Holdings has a current ratio of 1.10. It generally indicates good short-term financial strength.

The historical rank and industry rank for Lee's Pharmaceutical Holdings's Current Ratio or its related term are showing as below:

STU:L1PA' s Current Ratio Range Over the Past 10 Years
Min: 1   Med: 1.59   Max: 3.85
Current: 1.02

During the past 13 years, Lee's Pharmaceutical Holdings's highest Current Ratio was 3.85. The lowest was 1.00. And the median was 1.59.

STU:L1PA's Current Ratio is ranked worse than
81.67% of 1020 companies
in the Drug Manufacturers industry
Industry Median: 1.98 vs STU:L1PA: 1.02

Lee's Pharmaceutical Holdings Current Ratio Historical Data

The historical data trend for Lee's Pharmaceutical Holdings's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lee's Pharmaceutical Holdings Current Ratio Chart

Lee's Pharmaceutical Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.31 1.04 1.00 1.01 1.02

Lee's Pharmaceutical Holdings Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 1.00 1.01 1.10 1.02

Competitive Comparison of Lee's Pharmaceutical Holdings's Current Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Lee's Pharmaceutical Holdings's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lee's Pharmaceutical Holdings's Current Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lee's Pharmaceutical Holdings's Current Ratio distribution charts can be found below:

* The bar in red indicates where Lee's Pharmaceutical Holdings's Current Ratio falls into.


;
;

Lee's Pharmaceutical Holdings Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Lee's Pharmaceutical Holdings's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=77.099/76.182
=1.01

Lee's Pharmaceutical Holdings's Current Ratio for the quarter that ended in Jun. 2024 is calculated as

Current Ratio (Q: Jun. 2024 )=Total Current Assets (Q: Jun. 2024 )/Total Current Liabilities (Q: Jun. 2024 )
=82.88/75.253
=1.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lee's Pharmaceutical Holdings  (STU:L1PA) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Lee's Pharmaceutical Holdings Current Ratio Related Terms

Thank you for viewing the detailed overview of Lee's Pharmaceutical Holdings's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lee's Pharmaceutical Holdings Business Description

Traded in Other Exchanges
Address
Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.

Lee's Pharmaceutical Holdings Headlines

No Headlines